Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Bausch & Lomb Acquires the Commercial Assets of Italian OphthalmicPharmaceuticals Company Tubilux

By Pharmaceutical Processing | October 5, 2009

Bausch & Lomb today announced it has acquired the commercial assets ofTubilux Pharma S.p.A. Tubilux is a privately held ophthalmic pharmaceuticals company thatdevelops and markets a range of proprietary, over-the-counter, and brandedgeneric products primarily in Italy, and with distribution in approximately 30other countries. Under the terms of the agreement, Bausch & Lomb has acquired the company’sophthalmic pharmaceuticals portfolio, as well as its commercial and salesoperations. Group Tubilux will retain its manufacturing operation, producingexisting products for Bausch & Lomb under a multi-year contract.”This agreement more than doubles our presence in the Italian ophthalmicpharmaceuticals market,” said Charl van Zyl, head of Bausch & Lomb’sPharmaceuticals business for Europe, Middle East and Africa. “Bausch & Lomb iscommitted to expanding our portfolio offerings, and we believe that thisinvestment will prove successful for the company, doctors and patients alike.”The acquired Tubilux portfolio includes products for dry eye relief(Oxyal, Lipimix, and Vitadrop); for glaucoma (Cebrolux and Timolux); foranti-infective use (Oftaquix); and for anti-inflammatory use (Fluaton).”As a result of this transaction, Tubilux will strengthen its focus andpresence in the ophthalmic pharmaceutical contract manufacturing sector,including ointments, gels and eye drop formats,” said Emidio Fedeli, chiefexecutive officer of Group Tubilux.

Related Articles Read More >

Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE